Tenax Therapeutics, Inc.
TENX
$6.00
-$0.04-0.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 194.76% | 125.75% | 35.56% | 19.69% | 3.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 168.77% | 153.90% | 136.74% | 108.65% | 58.08% |
| Operating Income | -168.77% | -153.90% | -136.74% | -108.65% | -58.08% |
| Income Before Tax | -150.42% | -139.63% | -128.26% | -107.00% | -57.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -150.42% | -139.63% | -128.26% | -107.00% | -57.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -150.42% | -139.63% | -128.26% | -107.00% | -57.57% |
| EBIT | -168.77% | -153.90% | -136.74% | -108.65% | -58.08% |
| EBITDA | 8.59% | -47.05% | -136.88% | -108.62% | -58.05% |
| EPS Basic | 85.39% | 89.91% | 84.16% | 86.98% | 92.37% |
| Normalized Basic EPS | 85.40% | 89.91% | 84.15% | 86.99% | 92.37% |
| EPS Diluted | 85.39% | 89.91% | 84.16% | 86.98% | 92.37% |
| Normalized Diluted EPS | 85.40% | 89.91% | 84.15% | 86.99% | 92.37% |
| Average Basic Shares Outstanding | 2,474.95% | 4,439.52% | 5,924.11% | 3,337.59% | 767.88% |
| Average Diluted Shares Outstanding | 2,474.95% | 4,439.52% | 5,924.11% | 3,337.59% | 767.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |